Stay updated on IcoSema vs. Glargine-Aspart in Type 2 Diabetes Clinical Trial
Sign up to get notified when there's something new on the IcoSema vs. Glargine-Aspart in Type 2 Diabetes Clinical Trial page.

Latest updates to the IcoSema vs. Glargine-Aspart in Type 2 Diabetes Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.3%
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe web page has been updated to reflect a new version, changing from v2.14.4 to v2.15.0.SummaryDifference0.9%
- Check32 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.3%
- Check75 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check89 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference5%
- Check97 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.3%
Stay in the know with updates to IcoSema vs. Glargine-Aspart in Type 2 Diabetes Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IcoSema vs. Glargine-Aspart in Type 2 Diabetes Clinical Trial page.